Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England.

Autor: Kirsebom FCM; UK Health Security Agency, London, UK. Freja.kirsebom@ukhsa.gov.uk., Andrews N; UK Health Security Agency, London, UK.; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK., Sachdeva R; UK Health Security Agency, London, UK., Stowe J; UK Health Security Agency, London, UK., Ramsay M; UK Health Security Agency, London, UK.; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK., Lopez Bernal J; UK Health Security Agency, London, UK. Jamie.LopezBernal2@ukhsa.gov.uk.; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK. Jamie.LopezBernal2@ukhsa.gov.uk.; NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK. Jamie.LopezBernal2@ukhsa.gov.uk.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Dec 12; Vol. 13 (1), pp. 7688. Date of Electronic Publication: 2022 Dec 12.
DOI: 10.1038/s41467-022-35168-7
Abstrakt: Despite the availability of the ChAdOx1-S booster vaccine, little is known about the real-world effectiveness although clinical trials have demonstrated enhanced immunity following a ChAdOx1-S booster. In England 43,171 individuals received a ChAdOx1-S booster whilst 13,038,908 individuals received BNT162b2 in the same period. ChAdOx1-S booster recipients were more likely to be female (adjusted odds ratio (OR) 1.67 (1.64-1.71)), in a clinical risk group (adjusted OR 1.58 (1.54-1.63)), in the clinically extremely vulnerable group (adjusted OR 1.84 (1.79-1.89)) or severely immunosuppressed (adjusted OR 2.05 (1.96-2.13)). The effectiveness of the ChAdOx1-S and BNT162b2 boosters is estimated here using a test-negative case-control study. Protection against symptomatic disease with the Omicron variant peaks at 66.1% (16.6 to 86.3%) and 68.5% (65.7 to 71.2%) for the ChAdOx1-S and BNT162b2 boosters in older adults. Protection against hospitalisation peaks at 82.3% (64.2 to 91.3%) and 90.9% (88.7 to 92.7%). For Delta, effectiveness against hospitalisation is 80.9% (15.6% to 95.7%) and 93.9% (92.8% to 94.9%) after ChAdOx1-S and BNT162b2 booster vaccination. This study supports the consideration of ChAdOx1-S booster vaccination for protection against severe COVID-19 in settings yet to offer boosters and suggests that individuals who received a ChAdOx1-S booster do not require re-vaccination ahead of others.
(© 2022. Crown.)
Databáze: MEDLINE
Externí odkaz: